For 2QFY2016, Glaxo Smithkline Pharma (GSK Pharma) reported a
disappointing set of numbers, due to lower- than-expected sales. Sales came in at
Rs692cr (V/s Rs720cr expected), a dip of 6.4% yoy, which was due to supply
constraints. On the operating front, the company’s gross margins for the quarter
came in at 56.4% V/s 53.5% in 2QFY2015. In spite of the rise in gross margins,
the OPM came in lower at 17.4% V/s an expected 20.2% and V/s 21.3% in
2QFY2015, mainly owing to lower sales during the quarter. Thus, the reported
net profit came in at Rs96cr V/s Rs129cr in 2QFY2015. However, the Adj. net profit
came in at Rs101cr V/s Rs129cr in 2QFY2015, a yoy dip of 21.4%. We remain
Neutral on the stock.
Results below our expectations: For 2QFY2016, GSK Pharma reported a
disappointing set of numbers, due to lower- than-expected sales. Sales came in at
Rs692cr (V/s Rs720cr expected), a dip of 6.4% yoy, which was due to supply
constraints. On the operating front, the company’s gross margins for the quarter
came in at 56.4% V/s 53.5% in 2QFY2015. In spite of the rise in gross margins,
the OPM came in lower at 17.4% V/s an expected 20.2% and V/s 21.3% in
2QFY2015, mainly owing to lower sales during the quarter. Thus, the reported
net profit came in at Rs96cr V/s `129cr in 2QFY2015. However, the Adj. net profit
came in at Rs101cr V/s Rs129cr in 2QFY2015, a yoy dip of 21.4%.
Outlook and valuation: The company has a strong balance sheet with cash of
~Rs2,000cr, which could be used for future acquisitions or higher dividend
payouts. On the operational front, we expect the company’s net sales to post a
CAGR of 9.8% to Rs3,158cr and EPS to register a mere CAGR of 6.6% to Rs68.3
over FY2015–17E. We remain Neutral on the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...